CYTR

CytRx Corporation Press Releases

$3.15
*  
0.03
0.96%
Get CYTR Alerts
*Delayed - data as of Mar. 4, 2015  -  Find a broker to begin trading CYTR now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
View:    CYTR Pre-Market
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks
Viewing
Filtered By
Ordered By
CytRx to Present at the Cowen & Company 35th Annual Health Care Conference
2/25/2015 9:00:00 AM - PR Newswire


CytRx to Present at the 17th Annual BIO CEO & Investor Conference on February 9, 2015 in New York City
2/2/2015 9:00:00 AM - PR Newswire


CytRx Announces Overall Survival Results from Its Global Phase 2b Clinical Trial of Aldoxorubicin in Soft Tissue Sarcoma
1/22/2015 9:00:00 AM - PR Newswire
▲3.96 % Price Change since this news event. The Volume Ratio is 2.22.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


CytRx Announces FDA's Removal of Partial Clinical Hold for Aldoxorubicin Clinical Trials Permitting Immediate Enrollment of New Patients
1/20/2015 6:00:00 AM - PR Newswire
▼-5.97 % Price Change since this news event. The Volume Ratio is 2.87.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


CytRx Announces Positive Interim Phase 2 Aldoxorubicin Results as a Treatment for HIV-Related Kaposi''s Sarcoma (KS)
1/8/2015 9:00:00 AM - PR Newswire
▼-8.16 % Price Change since this news event. The Volume Ratio is 1.83.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


CytRx Announces Positive Interim Phase 2 Aldoxorubicin Results in Glioblastoma Multiforme (Brain Cancer)
1/6/2015 6:00:00 AM - PR Newswire
▲10.53 % Price Change since this news event. The Volume Ratio is 25.16.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day